ClinicalTrials.gg
CompletedNCT03400995Updated Sep 11, 2018

A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

A Phase 1 interventional study of AK0529 in Healthy, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-11.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
Male
01

Study summary

This phase I study is to assess the mass balance recovery after a single oral dose of [14C]-AK0529 in healthy male subjects.

Read the detailed description

This is a single centre, single-dose, non-randomised, open label study. The primary objectives of this study are to assess the mass balance recovery and provide biosamples for metabolite profiling and structural identification after a single oral dose of [14C]-AK0529 in healthy male subjects. 7 subjects will be recruited to receive a single oral administration of a solution containing 300 mg AK0529. The total duration of the study will be approximately 6 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males
  • Aged between 30 and 55 years of age, inclusive
  • of 18.0 to 35.0 kg/m2, inclusive, or, if outside the range, considered not by the investigator and the medical monitor
  • Must be willing and able to communicate and participate in the whole study
  • Must have regular daily bowel movements
  • Must provide written
  • Must agree to use an adequate method of

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received any IMP in a clinical research study within the previous 3 months
  • Subjects who are study site or sponsor employees, or immediate family members of a study site or sponsor employee
  • Subjects who have previously been enrolled in this study
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption >21 units per week
  • Current smokers and those who have smoked within the last 12 months
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • Radiation exposure. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  • Abnormal liver function as assessed by clinical chemistry
  • Positive drugs of abuse test result
  • Positive , Ab or results
  • Evidence of renal impairment at screening
  • History of cardiovascular, renal, hepatic, chronic respiratory, neurological, dermatological or GI disease, or psychiatric disorder, as judged by the investigator
  • Any abnormality of parameters
  • Any abnormality of cardiac rhythm or history thereof
  • Serious adverse reaction or serious to any drug or the formulation
  • Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed, unless it is active at screening or admission
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal or any other 'alternative' remedies in the 14 days before IMP administration
  • Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Intervention Arm

    Each subject will receive a single oral administration of a solution containing 300 mg radiolabeled AK0529 in the fasted state.

    Drug: AK0529

Interventions

  • DrugAK0529

    A solution containing 300 mg radiolabelled AK0529.

06

What researchers measure

Primary outcomes

  1. Amount excreted (Ae)

    The amount of total radioactivity eliminated.

    Time frame: At approximately 6 weeks

  2. Percentage of the administered dose (%Ae)

    The amount of total radioactivity eliminated expressed as a percentage of the dose administered.

    Time frame: At approximately 6 weeks

  3. Cumulative recovery (CumAe)

    The cumulative amount of total radioactivity eliminated.

    Time frame: At approximately 6 weeks

  4. Percentage of cumulative recovery of the administered dose (Cum%Ae)

    The cumulative amount of total radioactivity eliminated expressed as a percentage of the dose administered.

    Time frame: At approximately 6 weeks

Secondary outcomes

  1. Percentage of Subjects with Adverse Events (AEs)

    An adverse event can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: From baseline up to approximately 6 weeks

07

Study locations

1 site
  • Quotient Clinical
    Nottingham, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Feb 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2018
First posted
Jan 17, 2018
StartActual
Jan 5, 2018
Primary completionActual
Feb 27, 2018
CompletionActual
Aug 30, 2018
Last update
Sep 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03400995
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 17, 2018
Start date
Jan 5, 2018
Primary completion
Feb 27, 2018
Completion
Aug 30, 2018
Last update
Sep 11, 2018

Study contacts

ArkBio Clinical Trial
study director · info@arkbiosciences.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion